BioForce Nanosciences Holdings (BioForce Nanosciences Holdings) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is BioForce Nanosciences Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. BioForce Nanosciences Holdings's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, BioForce Nanosciences Holdings could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for BioForce Nanosciences Holdings's Cash-to-Debt or its related term are showing as below:

BFNH' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

During the past 13 years, BioForce Nanosciences Holdings's highest Cash to Debt Ratio was No Debt. The lowest was No Debt. And the median was No Debt.

BFNH's Cash-to-Debt is ranked better than
99.89% of 1853 companies
in the Consumer Packaged Goods industry
Industry Median: 0.53 vs BFNH: No Debt

BioForce Nanosciences Holdings Cash-to-Debt Historical Data

The historical data trend for BioForce Nanosciences Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

BioForce Nanosciences Holdings Cash-to-Debt Chart

BioForce Nanosciences Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

BioForce Nanosciences Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of BioForce Nanosciences Holdings's Cash-to-Debt

For the Packaged Foods subindustry, BioForce Nanosciences Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioForce Nanosciences Holdings's Cash-to-Debt Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, BioForce Nanosciences Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where BioForce Nanosciences Holdings's Cash-to-Debt falls into.

BioForce Nanosciences Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

BioForce Nanosciences Holdings's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

BioForce Nanosciences Holdings had no debt ⁽¹⁾.

BioForce Nanosciences Holdings's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

BioForce Nanosciences Holdings had no debt ⁽¹⁾.

BioForce Nanosciences Holdings (OTCPK:BFNH) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

BioForce Nanosciences Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of BioForce Nanosciences Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

BioForce Nanosciences Holdings (BioForce Nanosciences Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » BioForce Nanosciences Holdings Inc (OTCPK:BFNH) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

2020 General Booth Boulevard, Suite 230, Virginia Beach, VA, USA, 23454

Website

http://www.bioforceeclipse.com

BioForce Nanosciences Holdings Inc is a provider of natural vitamins, minerals, and other nutritional supplements, powders, and beverages. It markets its products through social media and telemarketing.

Executives

Richard Kaiser Kaiser	director, 10 percent owner, officer: Secretary/Acting CFO	3419 VIRGINIA BEACH BLVD, UNIT 252, VIRGINIA BEACH VA 23452
Merle Ferguson	director, 10 percent owner, officer: CEO/President/Treasurer	2020 GENERAL BOOTH BLVD., SUITE 230, VIRGINIA BEACH VA 23454
Susan Donohue	10 percent owner	19001 S. RICHFIELD AVE, #102, GREEN VALLEY AZ 85614
Michael D Dunham	director	12000 W PARK PL, EFFECTIVE MANAGEMENT SYSTEMS INC, MILWAUKEE WI 53224
Gregory D Brown	officer: Chief Financial Officer	BIOFORCE NANOSCIENCES HOLDINGS, INC., 1615 GOLDEN ASPEN DRIVE - SUITE 101, AMES IA 50010-8098
Kerry M Frey	officer: Chief Operating Officer	BIOFORCE NANOSCIENCES HOLDINGS, INC., 1615 GOLDEN ASPEN DRIVE - SUITE 101, AMES IA 50010
Eric Henderson	director, 10 percent owner	BIOFORCE NANOSCIENCES HOLDINGS, INC., 1615 GOLDEN ASPEN DRIVE, SUITE 101, AMES IA 50010
Lawrence Marshall Gold	director	830 MENLO AVENUE, SUITE 100, MENLO PARK CA 94025
Jean-jacques Sunier	director	BIOFORCE NANOSCIENCES HOLDINGS, INC., 1615 GOLDEN ASPEN DRIVE, SUITE 101, AMES IA 50010
Societe Generale Asset Management Alternative Investments	10 percent owner	170, PLACE HENRI REGNAULT, LADEFENSE, PARIS I0 92043
Ed Cowle	10 percent owner	6 EAST 45TH ST., SUITE 1000, NEW YORK NY 10017
H Deworth Williams	10 percent owner	2681 EAST PARLEYS WAY, SUITE #204, SALT LAKE CITY UT 84109
Carter Robert P Iii	10 percent owner	25 RADCLIFFE DRIVE, VOORHEES NJ 08043
Harvey N Kaye	10 percent owner	190 NW SPANISH RIVER BLVD., SUITE 101, BOCA RATON FL 33431

BioForce Nanosciences Holdings (BioForce Nanosciences Holdings) Headlines

No Headlines

BioForce Nanosciences Holdings (BioForce Nanosciences Holdings) Cash-to-Debt : No Debt (1) (As of Dec. 2023)